文献速递神经肿瘤

MIB-1指数在脑膜瘤中的预后价值:一项用于确定复发与生存最佳截断值的回顾性队列研究

Prognostic value of MIB-1 index in meningioma: a retrospective cohort study to establish an optimal cutoff for recurrence and survival.
PubMed 文献 · J Neurooncol · 2025-05-12

该回顾性队列纳入404例脑膜瘤切除术患者,用ROC分析确定MIB-1预测复发与生存的最佳截断值为4.1%(复发AUC=0.661,p<0.001;生存AUC=0.717,p<0.001)。MIB-1≥4.1%者复发风险HR=2.9(p=0.009)、死亡风险HR=2.8(p=0.036),无复发生存期与总生存期均更短。

要点

  • MIB-1最佳截断值4.1%由ROC的Youden指数确定,预测复发AUC=0.661。
  • MIB-1≥4.1%组复发风险HR=2.9(p=0.009),死亡风险HR=2.8(p=0.036)。
  • MIB-1≥4.1%组无复发生存期119.0个月 vs 129.0个月,总生存期163.0个月 vs 229.0个月。

核心结论

  • 确定MIB-1指数最佳截断值4.1%,可独立预测脑膜瘤切除术患者的复发、死亡及更短的无复发生存期和总生存期。
  • 作者认为该阈值可作为辅助预后工具,用于细化风险分层并指导术后管理。

研究设计与样本

  • 回顾性研究,纳入404例接受脑膜瘤切除术的患者。
  • 中位年龄55.0岁(范围16-85),女性占72.3%。
  • 队列以WHO 1级(69.6%)和2级(30.0%)脑膜瘤为主。
  • 用ROC分析确定MIB-1预测复发与生存的最佳截断值并计算AUC,再用于Kaplan-Meier生存分析和多变量Cox回归,校正年龄、性别、肿瘤直径、肿瘤位置、切除程度和辅助放疗。

主要发现

  • ROC分析确定MIB-1最佳截断值为4.1%,预测复发AUC=0.661(p<0.001),预测生存AUC=0.717(p<0.001)。
  • 241例(59.7%)MIB-1<4.1%,163例(40.3%)MIB-1≥4.1%。
  • MIB-1≥4.1%组复发风险HR=2.9(p=0.009),死亡风险HR=2.8(p=0.036)。
  • MIB-1≥4.1%组无复发生存期119.0个月 vs 129.0个月(p<0.001),总生存期163.0个月 vs 229.0个月(p<0.001)。

关键数值与推荐

  • MIB-1预测复发的最佳截断值为4.1%,AUC=0.661(p<0.001)。
  • MIB-1预测生存的最佳截断值为4.1%,AUC=0.717(p<0.001)。
  • MIB-1≥4.1%组复发HR=2.9(p=0.009),死亡HR=2.8(p=0.036)。
  • MIB-1≥4.1%组无复发生存期119.0个月 vs 129.0个月(p<0.001),总生存期163.0个月 vs 229.0个月(p<0.001)。

临床怎么用

  • 作者认为MIB-1指数4.1%可作为辅助预后工具,用于细化风险分层并指导术后管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Predicting long-term outcomes after meningioma resection remains challenging. Ki-67/MIB-1 correlates with recurrence, yet its optimal cutoff is undefined. This study aims to establish a threshold that enhances risk stratification, improves recurrence prediction, and informs postoperative surveillance and adjuvant treatment strategies. METHODS: This is retrospective study of patients who underwent meningioma resection. Receiver operating characteristic (ROC) analysis determined the optimal MIB-1 cutoff for predicting recurrence and survival, providing area under the curve (AUC). This cutoff was then applied in Kaplan-Meier survival analyses and multivariable Cox regressions, controlling for age, sex, tumor diameter, tumor location, extent of resection, and adjuvant radiotherapy. RESULTS: A total of 404 patients were included. Median age was 55.0 years (range: 16-85) and 72.3% were female. The cohort primarily consisted of WHO Grade 1 (69.6%) and Grade 2 (30.0%) meningiomas. An optimal MIB-1 index cutoff of 4.1% was identified using ROC analysis with the Youden index for predicting recurrence (AUC = 0.661, p < 0.001) and survival (AUC = 0.717, p < 0.001). 241 patients (59.7%) had a MIB-1 < 4.1%, and 163 (40.3%) had a MIB-1 ≥ 4.1%. Patients with MIB-1 ≥ 4.1% had a higher risk of recurrence (HR = 2.9, p = 0.009) and mortality (HR = 2.8, p = 0.036). Patients with MIB-1 ≥ 4.1% demonstrated shorter recurrence-free survival (RFS) (119.0 vs. 129.0 months, p < 0.001) and overall survival (OS) (163.0 vs. 229.0 months, p < 0.001). CONCLUSION: We identified an optimal and actionable MIB-1 index cutoff of 4.1% which independently predicted recurrence, mortality, and shorter RFS and OS for patients undergoing meningioma resection. As the first study to establish and validate this threshold, our findings highlight its potential as an adjunct prognostic tool to refine risk stratification and guide postoperative management.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Shukla IY, Ebada A, Bever N, et al. Prognostic value of MIB-1 index in meningioma: a retrospective cohort study to establish an optimal cutoff for recurrence and survival. J Neurooncol. 2025. PMID: 40353934. doi:10.1007/s11060-025-05057-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。